摘要
目的 探讨替米沙坦联合左旋氨氯地平对原发性高血压合并2型糖尿病微量蛋白尿的影响.方法 将219例原发性高血压合并2型糖尿病微量蛋白尿的阳性患者随机分为替米沙坦（对照A组）,左旋氨氯地平（对照B组）,替米沙坦联合左旋氨氯地平（观察组）.每组各73例,三组治疗24w,观察3组患者治疗前后24 h动态血压、糖化血红蛋白、24 h尿微量蛋白的变化.结果 三组患者治疗24 w后,观察组总有效率98.63%,对照A组则为82.19%,对照B组80.82%.观察组较对照A、B组血压均明显下降（P＜0.05）,治疗后观察组微量蛋白尿较对照A、B两组明显下降（p＜0.05）.结论 替米沙坦联合左旋氩氯地平对原发性高血压合并2型糖尿病微量蛋白尿的患者治疗,能够较好地控制血压,明显降低微量蛋白尿,保护肾功能,值得在基层医院大力推广应用.
Objective To investigate the influence of the telmisartan combined with levamlodipine besylate tablets in treatment for the microalbuminuria of primary hypertension patients with Type 2 diabetes mellitus. Methods 219 masculine cases of primary hypertension with Type 2 diabetes mellitus patients were randomly divided into telmisartan group （control group A）, levamlodipine besylate group （control group B）, and telmisartan combined with levamlodipine besylate group（observation group）, 73 cases for each group, three groups were treated for 24 weeks, to observe the change of 24 hours ambulatory blood pressure, glycosylated hemoglobin and 24-hour microalbuminuria before and after treatment. Results 24 weeks after treatment, the total effective rate of the observation group was 98.63%, while those of the control group A and control group B were 82.19% and 80.82% respectively, the observation group was lower than the control group A and B （P〈0.05）, the blood pressure and microalbuminuria in observation group were obviously lower than those in the control group A and B （P〈0.05）.Conclusion It suggested that the telmisartan combined with levamlodipine besylate tablets in treatment for the microalbuminuria of primary hypertension patients with Type 2 diabetes mellitus could effectively contrel the blood pressure, obviously reduce the microalbuminuria and protect renal function. It is worthy for primary hospitals to spread and exploitation.
出处
《国际医药卫生导报》
2011年第14期1735-1738,共4页
International Medicine and Health Guidance News
关键词
原发性高血压合并2型糖尿病
替米沙坦
左旋氨氯地平
Primary hypertension patients with Type 2 diabetes mellitus
Telmisartan
Levamlodipine besylate tablets
